Gapping up
In reaction to strong earnings/guidance: SNX +7.8%, ( also increased quarterly cash dividend), THO +1.3%, .
M&A news:
In reaction to strong earnings/guidance: SNX +7.8%, ( also increased quarterly cash dividend), THO +1.3%, .
M&A news:
- GI +88.9% (to be acquired by Boston Scientific (BSX) for $8.00/share)
- RMP +2.8% (ticking higher, will purchase the acquired midstream assets from Rice Energy for $600 mln. The transaction is expected to close in the fourth quarter of 2016, subject to customary closing conditions)
Other news:
- INFI +12.4% (presents new preclinical data for IPI-549 that "appear favorable")
- KITE +11.9% (announces positive topline KTE-C19 data from ZUMA-1 pivotal trial in patients with aggressive non-hodgkin lymphoma (NHL) -- Study met primary endpoint with combined complete response rate of 39% at three months)
- ARRY +11.2% (cont strength)
- PPHM +10.2% (presentation of preclinical study data demonstrating that PS-targeting antibodies similar to bavituximab)
- PIRS +10.1% (Pieris Pharmaceuticals presents 'positive' data for its bispecific drug candidate, PRS-343)
- NYRT +8.2% (files for 3,452,7 share common stock offering by selling shareholders; retains Spencer Stuart for independent Board Of Directors candidate search)
- PERI +8% (CEO to step down; Directors to begin search for new CEO)
- JUNO +6.7% (following KITE's CAR-T data)
- DNAI +5.9% (obtains an exclusive license from the CRT Pioneer Fund LP for worldwide rights to develop and commercialize PNT737)
- ATNM +5% (initiates a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia who are over the age of 60)
- BLDP +4.9% (announces that automotive OEM Audi AG has issued purchase orders to accelerate certain key development activities)
- HEAR +4.3% (light volume, restructuring Hypersound business to substantially lower operating costs)
- NAVB +4.1% (appoints Michael Goldberg, M.D. President and Chief Executive Officer and Eric Rowinsky, M.D. as Chairman)
- PTIE +3.8% (after Monday's 50% decline on CRL news)
- DRRX +2.6% (after Monday's 30%+ decline on CRL news)
- AGRO +2.4% (Adecoagro S.A. extends share repurchase program for and additional twelve-month period ending on September 23, 2017)
- TRIL +1.3% (presents data indicating TTI-621 signal leads to enhanced anti-tumor CD8 + T cell responses)
- NQ +1% (announces Zhongzhi Hitech Overseas Investment agreed to purchase $220 mln convertible notes through a private placement)
Analyst comments:
- ORAN +2.2% (upgraded to Outperform from Neutral at Credit Suisse)
- LLY +1.5% (upgraded to Buy from Neutral at Goldman)
- AZO +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AMZN +0.6% (target raised to $1000 from $925 at JP Morgan)
- CBOE +0.6% (upgraded to Neutral from Underperform at Credit Suisse)